Writing Group Disclosures
| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Gissette Reyes-Soffer | Columbia University | Amgen, Inc. (responsible for regulatory IRB for CUIMC [site])* | None | None | None | None | None | None |
| Marlys L. Koschinsky | University of Western Ontario, Robarts Research Insitute (Canada) | Canadian Institutes of Health Research†; Natural Sciences and Engineering Research Council†; Abcentra* | None | Novartis Canada* | None | None | Ayma Therapeutics* | University of Western Ontario (professor)† |
| Lars Berglund | University of California, Davis | None | None | None | None | None | None | None |
| P. Barton Duell | Oregon Health and Science University, Knight Cardiovascular Institute | None | None | None | None | None | None | None |
| Henry N. Ginsberg | Columbia University Irving Institute | Amgen (Site PI on a phase 2a/b trial of Amgen’s siRNA against apo(a). The grant from Amgen supports the nurse practitioner and study costs. He does not receive any salary or other types of funds from the research grant.)† | None | None | None | None | Amgen*; Silence Therapeutics* | None |
| Sean P. Heffron | New York University School of Medicine | None | None | None | None | None | None | None |
| Pia R. Kamstrup | Herlev and Gentofte Hospital, Copenhagen University Hospital (Denmark) | None | None | None | None | None | None | None |
| Donald M. Lloyd-Jones | Northwestern University, Feinberg School of Medicine | None | None | None | None | None | None | None |
| Santica M. Marcovina | Medpace Reference Laboratories | None | None | Novartis* | None | None | Denka-Seiken*; Roche Diagnostics* | None |
| Calvin Yeang | University of California San Diego | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.